Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics shareholders approve 2026 Stock Incentive Plan at annual meeting

Neutral Impact 2 of 5 shareholder Written later

At its June 26, 2026 annual meeting, United Therapeutics shareholders approved the 2026 Stock Incentive Plan, which adds 1,500,000 new shares to the pool along with shares left unused under the prior 2015 plan. The plan passed with 25,872,075 votes for and 10,070,290 against, and it lets the company grant options, restricted stock, RSUs and other awards, which can increase the number of shares outstanding over time.

Key points

  • The 2026 Plan received 25,872,075 votes for, 10,070,290 against, 276,512 abstentions and 1,194,857 broker non-votes.
  • The plan covers 1,500,000 new shares plus 2,413,730 shares remaining under the prior plan as of June 26, 2026.
  • Shareholders also ratified Ernst & Young LLP as independent auditor for 2026, with 35,753,887 votes for and 1,647,415 against.
  • Each of the 12 director nominees received more votes for than against, and each serves a one-year term.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECJun 29, 2026, 4:32 PM ET
Accession number0001104659-26-078865

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.